NMDA

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on: 
Wednesday, March 27, 2024
Algernon, Brain, Drug discovery, Letter, NMDA, Acquisition, Patient, AGN, Ifenprodil, IPF, Idiopathic pulmonary fibrosis, USD, Chronic cough, Food, Pharmaceutical industry

The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.

Key Points: 
  • The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.
  • Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling.
  • Ifenprodil is one of Algernon’s lead research programs and represents a novel first-in-class potential treatment for chronic cough.
  • It is thought to interfere with central signalling in the brain, suppressing the urge to cough.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Relief Mental Health Honors Psychiatric Nurse Practitioner Susan Chapman as Provider of the Month

Retrieved on: 
Tuesday, March 12, 2024
Pharmaceutical, Health, Nursing, Mental Health, Depression, Mental health, Grammatical mood, NMDA, Trust, Mental, Patient, Transcranial magnetic stimulation, TMS, OCD, Month, Empowerment, FDA, Emotion, Food

Relief Mental Health proudly announces Susan Chapman MSN, APNP, FNP-BC, PMHNP-BC, psychiatric nurse practitioner, as its distinguished Provider of the Month.

Key Points: 
  • Relief Mental Health proudly announces Susan Chapman MSN, APNP, FNP-BC, PMHNP-BC, psychiatric nurse practitioner, as its distinguished Provider of the Month.
  • With a focus on innovative solutions, Susan specializes in SPRAVATO® , offering hope and relief to those facing persistent challenges with depression.
  • Susan Mueller, CEO of Relief Mental Health, commends Chapman’s exceptional care, stating, "Susan Chapman exemplifies the highest standards of patient care and commitment.
  • Relief Mental Health is honored to recognize Susan Chapman as its Provider of the Month, highlighting her contributions to the field of mental health care and dedication to patient well-being.

NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

Retrieved on: 
Monday, March 25, 2024
Suicide, Depression, Conference, HOPE, Science, NMDA, Patient, CNS, Efficacy, Therapy, Risk, Neurotoxicity, Spectrum, PTSD, Pharmaceutical industry

RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.

Key Points: 
  • RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
  • The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders.
  • Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced."
  • "HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Fauna Bio Announces Dr. Lara Do Amaral-Silva as Recipient of the CEPS FaunaBio Translational Research Award

Retrieved on: 
Monday, March 4, 2024
Oxygen, Wake Forest University, Breakfast, Animal, Physiology, Hypoxia, Myenteric plexus, Health, DSM-IV codes, APS, NMDA, Mammal, American Physiological Society, Genomics, Biology, Hibernation, Research, Human, Brain, Medical device

EMERYVILLE, Calif., March 4, 2024 /PRNewswire/ -- Fauna Bio, biotechnology company improving human health by leveraging animal genomics, announced today Dr. Lara Do Amaral-Silva, assistant professor of biology at Wake Forest University, as the recipient of the FaunaBio Translational Research Award through the American Physiological Society (APS).

Key Points: 
  • Her research focuses on the physiology of animals that can overcome metabolic challenges in the brain to gain overarching insights into brain diseases.
  • "While Fauna Bio is focused on data and discovery from mammals, we recognize there is important translational work being done in a broader range of species.
  • This important research highlights the resilience of brain function in animals under challenging conditions that would be fatal to humans," said Ashley Zehnder, Ph.D., CEO & Co-Founder, Fauna Bio.
  • The research also identified specific NMDA receptor subunits, GluN2B and GluN2C, as key players in mediating the NMDA receptor current.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, PD, Research, Sale, Tremor, Health care, NMDA, Innovation, Webcast, Plasma, Incidence, GABAA, CIV, Standard of care, Deficit spending, Therapy, European Medicines Agency, Food and Drug Administration, MCI, NEST, HCP, Woman, Schedule, USAN, Postpartum depression, ODD, Safety, Prescription, Insurance, EMA, FDA, Food, Passport, DEA, PAM, DSM-IV codes, Risk, PPD, Patient, MHRA, Cognition, Essential tremor, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, February 7, 2024
Mortality, Heidelberg University, ALS, Research, Fundamental, NMDA, Patient, Excitotoxicity, Yan, TRPM4, Pharmaceutical industry

Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Key Points: 
  • Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
  • The study provides seminal preclinical proof-of-concept data for the treatment of amyotrophic lateral sclerosis (ALS).
  • Most importantly, the validated ALS clinical biomarker neurofilament light chain (Nf-L) was reduced in line with the positive treatment effects.
  • TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration.

Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder

Retrieved on: 
Wednesday, January 24, 2024
Research, Mental Health, Medical Devices, Neurology, Clinical Trials, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Patient, Sleep, EEG, Food and Drug Administration, NMDA, Mental health, Algorithm, NMDAR, Neuropsychiatry, Depression, Food, Neuroscience, Cognition, DSM-IV codes, FDA, Biomarker, Myenteric plexus, Gate, Clinical trial, Diagnosis, Medicine, Beacon, MDD, Medical imaging

Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.

Key Points: 
  • Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.
  • Zelquistinel is a rapid-acting, once-weekly oral NMDA receptor positive modulator in development for treating major depressive disorder (MDD).
  • “The Gate team is excited to partner with Beacon in pioneering a new era of precision psychiatry with innovative biomarker insights, approaches, and technology,” commented Mike McCully, CEO of Gate Neurosciences.
  • The Dreem™ 3S data flows into Beacon Biosignals' analytics platform to provide validated neurophysiological endpoints for clinical trials.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Retrieved on: 
Tuesday, January 16, 2024
Intellectual property, Death, Clostridioides difficile infection, Patient, Research, DSM-IV codes, Hospital, Health, Urine, Dark Enlightenment, Colitis, Tuberculosis, UTI, Clostridioides difficile, DCS, Tetracycline, QIDP, Risk, Infection, Cephalosporin, Pulmonary fibrosis, Sepsis, FDA, Priority review, Penicillin, New Drug Application, Pyelonephritis, Urinary tract infection, Literature, Contra, NMDA, CNS, Pharmaceutical industry

Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.

Key Points: 
  • Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.
  • The FDA also granted NRX-101 Fast Track designation for cUTI, which additionally allows for rolling submission of the Company's New Drug Application.
  • On the basis of this advance, NRx is seeking partners with active involvement in urology, infectious disease and/or women's health for commercialization of NRX-101.
  • NRx thanks the US FDA for its rapid award of QIDP designation for cUTI and pyelonephritis.